title: First experience in application of heparin-induced extracorporeal LDL precipitation (H.E.L.P.) in acute thromboembolic stroke.
abstract: Heparin-induced Extracorporeal LDL < total cholesterol, triglycerides, fibrinogen > Precipitation (H.E.L.P.) was applied in cases of acute thromboembolic stroke within 48 to 96 hours after onset. 42 patients had been randomized for the trial. In Group A 12 patients underwent a single H.E.L.P. application, while remaining 10 patients formed a control group. In group B 10 patients had 10 H.E.L.P. applications, the other 10 patients firmed as controls. Results of group A: 4 days after H.E.L.P. an improvement in the Mathew Scale and in the Mini Mental State Examination could be obtained (p < 0.05 each). 10 days after H.E.L.P. all the tests showed significant changes (p < 0.05 in the Mathew Scale and in the Mini Mental State Examination and p < 0.01 in the Activities-of-Daily-Living Score). Relatet to the controls there appeared a statistically significant difference 4 days after H.E.L.P. in the Mini Mental State Examination and in the Activities-of-Daily-Living Score (p < 0.05 each). At day 10 all the tests showed a difference to the controls (p < 0.05 in the Mathew Scale and p < 0.01 in the other tests). Results of group B 10: One day after 1st H.E.L.P. a statistically significant difference could be observed in all the tests (p < 0.05 in the Mathew Scale and the Mini Mental State Examination and p < 0.01 in the Activities-of-Daily-Living Score). At that time even a difference to the controls became visible (p < 0.05 in the Mathew scale, p < 0.01 in the other tests).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Neurology, Karl-Frazens University of Graz.
authors.forename: H
authors.initials: H
authors.lastname: Lechner
authors.forename: M
authors.initials: M
authors.lastname: Walzl
authors.forename: B
authors.initials: B
authors.lastname: Walzl
authors.forename: G
authors.initials: G
authors.lastname: Kleinert
mesh_terms: D000203:Activities of Daily Living; D002561:Cerebrovascular Disorders / Q000209:etiology* / Q000503:physiopathology; D011232:Chemical Precipitation; D005112:Extracorporeal Circulation; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000150:complications* / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000302:isolation & purification*; D008297:Male; D008609:Mental Status Schedule; D008875:Middle Aged; D012720:Severity of Illness Index
chemical_list: D008077:Lipoproteins, LDL; D006493:Heparin